Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia

The prognosis for adult and pediatric patients with Philadelphia chromosome -positive (Ph+) acute lymphoblastic leukemia (ALL) treated with chemotherap y alone is extremely poor. An overview of the biology and clinical features of Ph+ ALL is presented in this review. The experience with chemotherapy a nd autologous stem cell transplantation (SCT) is summarized. Allogeneic SCT offers a curative option for patients who have an appropriately matched do nor. Variables affecting outcome after allogeneic SCT, including age, stage of disease, source of stem cells, preparatory regimen, and molecular and c ytogenetic details, are analyzed. The City of Hope/Stanford University expe rience with fractionated total body irradiation and high-dose etoposide is described, and future directions for monitoring and treating minimal residu al disease are discussed.